Abstract
Solar ultraviolet (sUV) irradiation is a major environmental carcinogen that can cause inflammation and skin cancer. The costs and morbidity associated with skin cancer are increasing, and therefore identifying molecules that can help prevent skin carcinogenesis is important. In this study, we identified the p53-related protein kinase (PRPK) as a novel oncogenic protein that is phosphorylated by the T-LAK cell-originated protein kinase (TOPK). Knockdown of TOPK inhibited PRPK phosphorylation and conferred resistance to solar-simulated light (SSL)-induced skin carcinogenesis in mouse models. In the clinic, acute SSL irradiation significantly increased epidermal thickness as well as total protein and phosphorylation levels of TOPK and PRPK in human skin tissues. We identified two PRPK inhibitors, FDA-approved rocuronium bromide (ZemuronĀ®) or betamethasone 17-valerate (BetadermĀ®) that could attenuate TOPK-dependent PRPK signaling. Importantly, topical application of either rocuronium bromide or betamethasone decreased SSL-induced epidermal hyperplasia, neovascularization, and cutaneous squamous cell carcinoma (cSCC) development in SKH1 (Crl: SKH1-Hrhr) hairless mice by inhibiting PRPK activation, and also reduced expression of the proliferation and oncogenesis markers, COX-2, cyclin D1, and MMP-9. This study is the first to demonstrate that targeting PRPK could be useful against sUV-induced cSCC development.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL. Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: a systematic review and meta-analysis. JAMA Dermatol. 2016;152:419ā28.
Guy GP Jr, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the U.S., 2002ā26 and 2007-2011. Am J Prev Med. 2015;48:183ā7.
Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol. 2015;151:1081ā6.
Brantsch KD, Meisner C, Schonfisch B, Trilling B, Wehner-Caroli J, Rocken M, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9:713ā20.
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277ā300.
Farasat S, Yu SS, Neel VA, Nehal KS, Lardaro T, Mihm MC, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol. 2011;64:1051ā9.
Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol. 2000;136:1524ā30.
Ratushny V, Gober MD, Hick R, Ridky TW, Seykora JT. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Investig. 2012;122:464ā72.
Fidler IJ. The pathogenesis of cancer metastasis: the āseed and soilā hypothesis revisited. Nat Rev Cancer. 2003;3:453ā8.
Muller-Decker K. Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence. Cancer Metastasis Rev. 2011;30:343ā61.
Trifan OC, Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med. 2003;7:207ā22.
Shen Y, Xu J, Jin J, Tang H, Liang J. Cyclin D1 expression in Bowenās disease and cutaneous squamous cell carcinoma. Mol Clin Oncol. 2014;2:545ā8.
Huang K, Huang C, Shan K, Chen J, Li H. Significance of PC cell-derived growth factor and cyclin D1 expression in cutaneous squamous cell carcinoma. Clin Exp Dermatol. 2012;37:411ā7.
Panelos J, Tarantini F, Paglierani M, Di Serio C, Maio V, Pellerito S, et al. Photoexposition discriminates Notch 1 expression in human cutaneous squamous cell carcinoma. Mod Pathol. 2008;21:316ā25.
Zhu F, Zykova TA, Kang BS, Wang Z, Ebeling MC, Abe Y, et al. Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. Gastroenterology. 2007;133:219ā31.
Oh SM, Zhu F, Cho YY, Lee KW, Kang BS, Kim HG, et al. T-lymphokine-activated killer cell-originated protein kinase functions as a positive regulator of c-Jun-NH2-kinase 1 signaling and H-Ras-induced cell transformation. Cancer Res. 2007;67:5186ā94.
Chang CF, Chen SL, Sung WW, Hsieh MJ, Hsu HT, Chen LH, et al. PBK/TOPK expression predicts prognosis in oral cancer. Int J Mol Sci. 2016;17:1007.
Joel M, Mughal AA, Grieg Z, Murrell W, Palmero S, Mikkelsen B, et al. Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo. Mol Cancer. 2015;14:121.
Abe Y, Matsumoto S, Wei S, Nezu K, Miyoshi A, Kito K, et al. Cloning and characterization of a p53-related protein kinase expressed in interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and the testes. J Biol Chem. 2001;276:44003ā11.
Abe Y, Takeuchi T, Imai Y, Murase R, Kamei Y, Fujibuchi T, et al. A small Ras-like protein Ray/Rab1c modulates the p53-regulating activity of PRPK. Biochem Biophys Res Commun. 2006;344:377ā85.
Peterson D, Lee J, Lei XC, Forrest WF, Davis DP, Jackson PK, et al. A chemosensitization screen identifies TP53RK, a kinase that restrains apoptosis after mitotic stress. Cancer Res. 2010;70:6325ā35.
Facchin S, Ruzzene M, Peggion C, Sartori G, Carignani G, Marin O, et al. Phosphorylation and activation of the atypical kinase p53-related protein kinase (PRPK) by Akt/PKB. Cell Mol Life Sci. 2007;64:2680ā9.
Shih MC, Chen JY, Wu YC, Jan YH, Yang BM, Lu PJ, et al. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene. 2012;31:2389ā400.
Bode AM, Dong Z. Molecular and cellular targets. Mol Carcinog. 2006;45:422ā30.
Runger TM. How different wavelengths of the ultraviolet spectrum contribute to skin carcinogenesis: the role of cellular damage responses. J Invest Dermatol. 2007;127:2103ā5.
Ridley AJ, Whiteside JR, McMillan TJ, Allinson SL. Cellular and sub-cellular responses to UVA in relation to carcinogenesis. Int J Radiat Biol. 2009;85:177ā95.
Lohmann CM, Solomon AR. Clinicopathologic variants of cutaneous squamous cell carcinoma. Adv Anat Pathol. 2001;8:27ā36.
Cherpelis BS, Marcusen C, Lang PG. Prognostic factors for metastasis in squamous cell carcinoma of the skin. Dermatol Surg. 2002;28:268ā73.
Yano K, Kajiya K, Ishiwata M, Hong YK, Miyakawa T, Detmar M. Ultraviolet B-induced skin angiogenesis is associated with a switch in the balance of vascular endothelial growth factor and thrombospondin-1 expression. J Invest Dermatol. 2004;122:201ā8.
Burton KA, Ashack KA, Khachemoune A. Cutaneous squamous cell carcinoma: a review of high-risk and metastatic disease. Am J Clin Dermatol. 2016;17:491ā508.
Yokogawa M, Takaishi M, Nakajima K, Kamijima R, Digiovanni J, Sano S. Imiquimod attenuates the growth of UVB-induced SCC in mice through Th1/Th17 cells. Mol Carcinog. 2013;52:760ā9.
Allanson M, Reeve VE. Carbon monoxide signalling reduces photocarcinogenesis in the hairless mouse. Cancer Immunol Immunother. 2007;56:1807ā15.
Katiyar SK. Interleukin-12 and photocarcinogenesis. Toxicol Appl Pharmacol. 2007;224:220ā7.
Schwarz A, Maeda A, Kernebeck K, van Steeg H, Beissert S, Schwarz T. Prevention of UV radiation-induced immunosuppression by IL-12 is dependent on DNA repair. J Exp Med. 2005;201:173ā9.
Katiyar SK. Proanthocyanidins from grape seeds inhibit UV-radiation-induced immune suppression in mice: detection and analysis of molecular and cellular targets. Photochem Photobiol. 2015;91:156ā62.
Edlund K, Larsson O, Ameur A, Bunikis I, Gyllensten U, Leroy B, et al. Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc Natl Acad Sci USA. 2012;109:9551ā6.
Loyo M, Li RJ, Bettegowda C, Pickering CR, Frederick MJ, Myers JN, et al. Lessons learned from next-generation sequencing in head and neck cancer. Head Neck. 2013;35:454ā63.
Missero C, Antonini D. Crosstalk among p53 family members in cutaneous carcinoma. Exp Dermatol. 2014;2:143ā6.
Matsuo Y, Park JH, Miyamoto T, Yamamoto S, Hisada S, Alachkar H, et al. TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Sci Transl Med. 2014;6:259ra145.
Li Y, Yang Z, Li W, Xu S, Wang T, Niu M, et al. TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c. Jun. Oncotarget. 2016;7:6748ā64.
Hensler S, Mueller MM. Inflammation and skin cancer: old pals telling new stories. Cancer J. 2013;19:517ā24.
Park JH, Jeong YJ, Won HK, Choi SY, Oh SM. Activation of TOPK by lipopolysaccharide promotes induction of inducible nitric oxide synthase through NF-kappaB activity in leukemia cells. Cell Signal. 2014;26:849ā56.
Fan X, Duan Q, Ke C, Zhang G, Xiao J, Wu D, et al. Cefradine blocks solar-ultraviolet induced skin inflammation through direct inhibition of T-LAK cell-originated protein kinase. Oncotarget. 2016;7:24633ā45.
Gao G, Zhang T, Wang Q, Reddy K, Chen H, Yao K, et al. ADA-07 suppresses solar ultraviolet-induced skin carcinogenesis by directly inhibiting TOPK. Mol Cancer Ther. 2017;16:1843ā54.
Saraceno R, Chiricozzi A, Nistico SP, Tiberti S, Chimenti S. An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis. J Dermatol Treat. 2010;21:363ā6.
Jensen JM, Scherer A, Wanke C, Brautigam M, Bongiovanni S, Letzkus M, et al. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis. Allergy. 2012;67:413ā23.
Dobrev H. Evaluation of the inhibitory activity of topical indomethacin, betamethasone valerate and emollients on UVL-induced inflammation by means of non-invasive measurements of the skin elasticity. Photodermatol Photoimmunol Photomed. 2001;17:184ā8.
Atzmony L, Reiter O, Hodak E, Gdalevich M, Mimouni D. Treatments for cutaneous lichen planus: a systematic review and meta-analysis. Am J Clin Dermatol. 2016;17:11ā22.
Nakagawa K, Taya Y, Tamai K, Yamaizumi M. Requirement of ATM in phosphorylation of the human p53 protein at serine 15 following DNA double-strand breaks. Mol Cell Biol. 1999;19:2828ā34.
Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell. 2011;20:79ā91.
Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 1993;53:4477ā80.
Kwon JY, Lee KW, Kim JE, Jung SK, Kang NJ, Hwang MK, et al. Delphinidin suppresses ultraviolet B-induced cyclooxygenases-2 expression through inhibition of MAPKK4 and PI-3 kinase. Carcinogenesis. 2009;30:1932ā40.
Kim JE, Kim JH, Lee Y, Yang H, Heo YS, Bode AM, et al. Bakuchiol suppresses proliferation of skin cancer cells by directly targeting Hck, Blk, and p38 MAP kinase. Oncotarget. 2016;7:14616ā27.
Kim JE, Roh E, Lee MH, Yu DH, Kim DJ, Lim TG, et al. Fyn is a redox sensor involved in solar ultraviolet light-induced signal transduction in skin carcinogenesis. Oncogene. 2016;35:4091ā101.
Acknowledgements
This work was supported by The Hormel Foundation and National of Institutes of Health grants CA027502, CA166011, CA187027, and CA196639 (ZD). We thank Dr. Lorenzo A. Pinna (Universita di Padova, Italy) for the pQE-81L-PRPK plasmid, Alyssa Langfald for confocal microscopy analysis, and Dr. Tia Rai and Nicki Brickman for assistance with manuscript submission.
Author contributions
ER and ZD designed the research. ER performed experiments and analyzed results. ER and AMB wrote the manuscript. ER and MHL performed animal studies. TAZ, HGK, KB, FZ, and YYC assisted in performing experiments. JN and YL performed computer modeling. AMB, CC, JE, and SED organized and supplied human patient tissues from University of Arizona Cancer Center.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
These authors contributed equally: Eunmiri Roh, Mee-Hyun Lee.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Roh, E., Lee, MH., Zykova, T.A. et al. Targeting PRPK and TOPK for skin cancer prevention and therapy. Oncogene 37, 5633ā5647 (2018). https://doi.org/10.1038/s41388-018-0350-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41388-018-0350-9
This article is cited by
-
The role of T-LAK cell-originated protein kinase in targeted cancer therapy
Molecular and Cellular Biochemistry (2022)
-
PBK phosphorylates MSL1 to elicit epigenetic modulation of CD276 in nasopharyngeal carcinoma
Oncogenesis (2021)
-
Crystal structure of the human PRPKāTPRKB complex
Communications Biology (2021)
-
Suppression of the solar ultraviolet-induced skin carcinogenesis by TOPK inhibitor HI-TOPK-032
Oncogene (2020)
-
T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics
Cell Death & Disease (2018)